KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Short term Debt (2019 - 2025)

Historic Short term Debt for Vir Biotechnology (VIR) over the last 5 years, with Q1 2025 value amounting to $17.5 million.

  • Vir Biotechnology's Short term Debt changed N/A to $17.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $17.5 million, marking a year-over-year change of. This contributed to the annual value of $16.1 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q1 2025, Vir Biotechnology's Short term Debt is $17.5 million.
  • Vir Biotechnology's 5-year Short term Debt high stood at $68.5 million for Q3 2021, and its period low was $16.1 million during Q4 2024.
  • For the 3-year period, Vir Biotechnology's Short term Debt averaged around $30.5 million, with its median value being $24.4 million (2021).
  • The largest annual percentage gain for Vir Biotechnology's Short term Debt in the last 5 years was 45744.68% (2021), contrasted with its biggest fall of 12803.74% (2021).
  • Over the past 3 years, Vir Biotechnology's Short term Debt (Quarter) stood at $68.5 million in 2021, then plummeted by 76.55% to $16.1 million in 2024, then grew by 8.97% to $17.5 million in 2025.
  • Its Short term Debt was $17.5 million in Q1 2025, compared to $16.1 million in Q4 2024 and $68.5 million in Q3 2021.